Do you want to read an article? Please log in or register.
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials
COPD
Related content
COMMENTED
COPD
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
doi: 10.1016/S2213-
AsthmaCOPD
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Lancet Respir Med.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M
doi: 10.1016/
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial
Am J Respir Crit Care Med.
Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.
doi: 10.1164/
RECOMMENDED
COPD
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis.
Sethi S, Donohue JF, Ferguson GT, Barnes CN, Crater GD
doi: 10.1177/1753466620905278.Visit the original publication at ncbi.nlm.nih.gov
COMMENTED
COPD
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev.
Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA
doi: 10.1002/14651858.
RECOMMENDED
COPD
Tiotropium in chronic obstructive pulmonary disease - a review of clinical development
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Anzueto A, Miravitlles M
doi: 10.1186/s12931-020-01407-y.
COMMENTED
COPD
Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS
Ann Am Thorac Soc.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, Barr RG, Krishnan JA, Lazarus SC, Cooper CB, Paine R 3rd, Peters SP, Hansel NN, Martinez FJ, Drummond MB, Current and former investigators of the SPIROMICS sites and reading centers
doi: 10.1513/AnnalsATS.201804-283OC.
RECOMMENDED
COPD
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials
Am J Respir Crit Care Med.
Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI
doi: 10.1164/rccm.
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease
Respir Med.
Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L
doi: 10.1016/j.rmed.2016.11.011.